跳至主要内容
临床试验/ACTRN12609000683235
ACTRN12609000683235招募中未知

Evaluation of a Web-Based Cognitive Rehabilitation Programme in Cancer Survivors with Self Reported Cognitive Impairment

Dr Janette Vardy0 个研究点目标入组 280 人开始时间: 2009年8月11日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Diagnosis of a primary malignancy for which definitive treatment was performed.
  • 2. Completed a minimum of 3 cycles of potentially curative chemotherapy within the last 6-60 months.
  • 3. Aged 18 years and above.
  • 4. Self reported changes in memory and concentration as per the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire –C30 Cognitive Functioning scale (EORTC-CF)
  • 5. Speak fluent English and read to a year 8 standard.
  • 6. Give written informed consent.
  • 7. Radiotherapy and/or immunotherapy (e.g. trastuzumab, lapatinib, bevacizumab or cetuximab) (if received) must have been completed at least 12 weeks prior to randomisation.
  • 8. Hormonal treatment (including tamoxifen or an aromatase inhibitor) is permitted providing treatment has been commenced at least 4 weeks prior to randomisation. Change of hormonal therapy should not be anticipated within the next 6 months, nor should it be likely to be ceased within 6 months.
  • 9. Easy access to computer and internet facilities.
  • 10. Participants are expected to be able to complete the study and be available for follow up.

排除标准

  • 1. Eastern Cooperative Oncology Group (ECOG) Performance Status of > 2.
  • 2. Any evidence of locally recurrent or metastatic disease.
  • 3. Any active psychiatric diagnosis or history of a cognitive disorder. Psychotropic medications are permitted if the patient is established on a stable regime and dosing schedule.
  • 4. Pre-existing neurological condition or any other co-morbidity, which would interfere with their ability to perform cognitive testing.
  • 5. Prior malignancy within the last 5 years (other than non-melanomatous skin cancer, cervical cancer in-situ and the cancer of interest for which they received their chemotherapy).
  • 6. Any previous chemotherapy other than that given for the cancer of interest.

研究者

发起方
Dr Janette Vardy

相似试验